Treatment of heroin (diamorphine) addiction: Current approaches and future prospects

Drugs

Volumn 62, Issue 9, 2002, Pages 1331-1343

  Gonzalez, Gerardo ^a   Oliveto, Alison ^a   Kosten, Thomas R ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BACLOFEN; BARBITURIC ACID DERIVATIVE; BUPRENORPHINE; CLONIDINE; DIAMORPHINE; KETOPROFEN; LEVACETYLMETHADOL; LOFEXIDINE; METHADONE; METHOHEXITAL; NALOXONE; NALTREXONE; OPIATE AGONIST; OPIATE ANTAGONIST; OXAZEPAM;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SCREENING; DRUG WITHDRAWAL; HEART ARRHYTHMIA; HEROIN DEPENDENCE; HUMAN; REVIEW; SEDATION; TREATMENT PLANNING; VERTIGO; WITHDRAWAL SYNDROME;

EID: 0036071124     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262090-00004     Document Type: Review

References (105)

1. A review of the drug abuse situation in the world
2. Drug abuse patterns in the United States
3. Treatment for opioid dependence: Quality and access
4. Effective medical treatment of opiate addiction. National consensus development panel on effective medical treatment of opiate addiction
5. Methadone maintenance therapy for opioid dependence: A guide to appropriate use
6. Opioid detoxification and maintenance with blocking agents
7. Withdrawal from methadone maintenance
8. Methadone maintenance
9. Buprenorphine for opiate addiction: Potential economic impact
10. Methadone maintenance in the treatment of opioid dependence: A current perspective
11. Retention in methadone maintenance and heroin addicts' risk of death
12. Mortality in heroin addiction: Impact of methadone treatment
13. An epidemiologic evaluation of long-term methadone maintenance treatment for heroin addiction
14. Mortality rates of persons entering methadone maintenance: A seven-year study
15. The cost-effectiveness of methadone maintenance as a health care intervention
16. Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors
17. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone
18. Including narcotic addiction treatment in an office-based practice
19. Outcomes of treatment of socially rehabilitated methadone maintenance patients in physicians' offices (medical maintenance): Follow-up at three and a half to nine and a fourth years
20. Methadone maintenance patients in general medical practice. A preliminary report
21. Opioid drugs in maintenance and detoxification treatment of opiate addiction. Substance Abuse and Mental Health Services Administration, HHS. Final rule
22. Outcome-oriented standards and performance indicators for substance dependency rehabilitation programs
23. Levo-alpha-acetylmethadol (LAAM) in the treatment of heroin addicts. I. Dosage schedule for induction and stabilization
24. Methadyl acetate and methadone as maintenance treatments for heroin addicts. A veterans administration cooperative study
25. Induction with levomethadyl acetate: Safety and efficacy
26. Dose-related efficacy of levomethadyl acetate for treatment of opioid dependence. A randomized clinical trial
27. Clinical experiences with 959 opioid-dependent patients treated with levo-alpha-acetylmethadol (LAAM)
28. Methadyl acetate (LAAM) in the treatment of heroin addicts. II. Double-blind comparison of gradual and abrupt detoxification
29. Injecting misuse of buprenorphine among French drug users
30. A multisite efficacy evaluation of a buprenorphine/naloxone product for opiate dependence treatment
31. Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine
32. The influence of drug-receptor kinetics on the pharmacological and pharmaco-kinetic profiles of buprenorphine
33. Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans
34. Examining the limits of the buprenorphine interdosing interval: Daily, every-third-day and every-fifth-day dosing regimens
35. Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet
36. Acute administration of buprenorphine in humans: Partial agonist and blockade effects
37. Clinical pharmacology of buprenorphine: Ceiling effects at high doses
38. Safety and side-effects of buprenorphine in the clinical management of heroin addiction
39. Safety of buprenorphine: No clinically relevant cardio-respiratory depression at high IV doses
40. Buprenorphine for the management of opioid withdrawal
41. Naltrexone shortened opioid detoxification with buprenorphine
42. Buprenorphine in opiate withdrawal: A comparison with clonidine
43. Opiate detoxification of methadone maintenance patients using lefetamine, clonidine and buprenorphine
44. A controlled comparison of buprenorphine and clonidine for acute detoxification from opioids
45. Three methods of opioid detoxification in a primary care setting. A randomized trial
46. Buprenorphine treatment of opioid dependence: A review
47. Effects of adding behavioral treatment to opioid detoxification with buprenorphine
48. A preliminary investigation of outcome following gradual or rapid buprenorphine detoxification
49. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomized clinical trial
50. Buprenorphine: An alternative to methadone for heroin dependence treatment
51. Buprenorphine responders: A diagnostic subgroup of heroin addicts?
52. Treatment of heroin addicts using buprenorphine
53. Buprenorphine versus methadone maintenance for opioid dependence
54. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence
55. Differences between general practitioner and addiction centre-prescribed buprenorphine substitution therapy in France. Preliminary results
56. Comparison of methadone and high dosage buprenorphine users in French care centres
57. Recent evolution in opiate dependence in France during generalisation of maintenance treatments
58. Buprenorphine-related deaths among drug addicts in France: A report on 20 fatalities
59. Deaths involving buprenorphine: A compendium of French cases
60. Effects of buprenorphine/naloxone in opioid-dependent humans
61. Endorphins, locus coerulus, clonidine and lofexidine: A mechanism for opiate withdrawal and new nonopiate treatments
62. Recent advances in opiate detoxification: Clonidine and lofexidine
63. Accelerated lofexidine treatment regimen compared with conventional lofexidine and methadone treatment for in-patient opiate detoxification
64. Double-blind study of lofexidine and clonidine in the detoxification of opiate addicts in hospital
65. Clonidine blocks acute opiate-withdrawal symptoms
66. Clonidine for opiate detoxification: Outpatient clinical trials
67. The clinical use of clonidine in abrupt withdrawal from methadone. Effects on blood pressure and specific signs and symptoms
68. Clonidine in out-patient detoxification from methadone maintenance
69. Clonidine produces a conditioned place preference in rats
70. Catecholaminergic mechanisms of reinforcement: Direct assessment by drug-self-administration
71. Two cases of clonidine abuse/dependence in methadone-maintained patients
72. Double-blind randomised controlled trial of lofexidine versus clonidine in the treatment of heroin withdrawal
73. Randomised double-blind comparison of lofexidine and clonidine in the out-patient treatment of opiate withdrawal
74. Lofexidine versus clonidine in rapid opiate detoxification
75. Clonidine and naltrexone in the outpatient treatment of heroin withdrawal
76. Opioid antagonists and adrenergic agonists for the management of opioid withdrawal
77. Primary care-based ambulatory opioid detoxification: The results of a clinical trial
78. Clonidine and opiate receptor antagonists in the treatment of heroin addiction
79. Rapid opiate detoxication in outpatient treatment: Relationship with naltrexone compliance
80. Clinical utility of rapid clonidine-naltrexone detoxification for opioid abusers
81. Naloxone treatment for opiate withdrawal syndrome
82. Acute blocking of naloxone-precipitated opiate withdrawal symptoms by methohexitone
83. Rapid and ultrarapid opioid detoxification techniques
84. Alternative strategies of opiate detoxification: Evaluation of the so-called ultra-rapid detoxification
85. Compliance to naltrexone treatment after ultra-rapid opiate detoxification: An open label naturalistic study
86. Pharmacologic treatment of heroin-dependent patients
87. Ultra-rapid opiate detoxification using deep sedation with oral midazolam: Short and long-term results
88. High risk of ultrashort noninvasive opiate detoxification
89. Opiate detoxification under anesthesia: No apparent benefit but suppression of thyroid hormones and risk of pulmonary and renal failure
90. State knew of risky heroin treatment before patient deaths
91. Opiate detoxification under anaesthesia
92. Outcome and six month follow up of patients after Ultra Rapid Opiate Detoxification (UROD)
93. Safety, efficacy, and long-term results of a modified version of rapid opiate detoxification under general anaesthesia: A prospective study in methadone, heroin, codeine and morphine addicts
94. Ultra rapid opiate detoxification as compared to 30-day inpatient detoxification program - A retrospective follow-up study
95. High-dose naltrexone and liver function safety
96. Naltrexone maintenance treatment for opioid dependence
97. The efficacy of naltrexone in preventing reabuse of heroin after detoxification
98. Clinical evaluation of naltrexone treatment of opiate-dependent individuals. Report of the national research council committee on clinical evaluation of narcotic antagonists
99. Patient response to naltrexone: Issues of acceptance, treatment effects, and frequency of administration
100. Follow-up after a six-month maintenance period on naltrexone versus placebo in heroin addicts
101. A naltrexone double blind placebo controlled study in Israel
102. Reassessing naltrexone maintenance as a treatment for illicit heroin users